Literature DB >> 19394075

The decade of NICE.

Michael D Rawlins1.   

Abstract

Mesh:

Year:  2009        PMID: 19394075     DOI: 10.1016/S0140-6736(09)60616-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins.

Authors:  Goodarz Danaei; Mohammad Tavakkoli; Miguel A Hernán
Journal:  Am J Epidemiol       Date:  2012-01-05       Impact factor: 4.897

2.  Drugs, money and society (Part II).

Authors:  Tom Walley
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

Review 3.  Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.

Authors:  Hans-Georg Eichler; Brigitte Bloechl-Daum; Eric Abadie; David Barnett; Franz König; Steven Pearson
Journal:  Nat Rev Drug Discov       Date:  2010-02-26       Impact factor: 84.694

4.  UK medicines policy: the role of clinical pharmacologists.

Authors:  David J Webb
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

5.  NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium.

Authors:  John A Ford; Norman Waugh; Pawana Sharma; Mark Sculpher; Andrew Walker
Journal:  BMJ Open       Date:  2012-01-30       Impact factor: 2.692

6.  Impact of NIHR HTA Programme funded research on NICE clinical guidelines: a retrospective cohort.

Authors:  Sheila Turner; Sheetal Bhurke; Andrew Cook
Journal:  Health Res Policy Syst       Date:  2015-08-22

7.  Study-design in pandemics: From surveillance and performance-evaluation to licensing and pharmacovigilance.

Authors:  Sheila M Bird
Journal:  Pharm Stat       Date:  2022-07       Impact factor: 1.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.